[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637118":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":35,"responsibleParty":52,"collaborators":21,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":21,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":21,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":21,"overallStatus":74,"whyStopped":21,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-MY PET Imaging","EXPERIMENTAL","All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-MY PET\u002FCT scans.After the participant rests quietly for 40 minutes or 1 hour, whole-body imaging of the head and torso will be performed using a United Imaging uEXPLORER Whole-Body PET\u002FCT scanner at 1 h, 2 h, and 3 h post-injection. The scan range will cover from the vertex to the upper third of the thighs. Participants who required a dynamic scan underwent a 40-min serial scan after injection of 68Ga-MY. PET\u002FCT static imaging was performed at 2 h and 3 h after injection.",[13,14],"Drug: 18F-FDG","Drug: 68Ga-MY",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"68Ga-MY","68Ga-MY is an investigational tracer, and all participants will undergo 68Ga-MY scanning.",[9],[27],{"name":28,"affiliation":5,"role":29},"Hua Zhu","PRINCIPAL_INVESTIGATOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},"CONTACT","010-88196495","zhuhuaBCH@pku.edu.cn",[36],{"facility":37,"status":21,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":28,"role":32,"phone":51,"phoneExt":21,"email":34},"+86 010-88196495",{"type":53,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100637118","5t4-targeting-nanobody-probe-for-pet-imaging-in-solid-tumors-100637118",false,"NCT07589101","5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors","Preparation of 5T4 Tumor Novel Target Nanobody PET Probe and Clinical Translation in Lung Cancer","Inclusion Criteria:\n\n1. Patients with solid tumors;\n2. Presence of measurable lesions on imaging examinations;\n3. Expected survival ≥12 weeks.\n\nExclusion Criteria:\n\n1. Severe hepatic or renal dysfunction;\n2. Women who are planning pregnancy, pregnant, or breastfeeding;\n3. Unable to remain in supine position for 30 minutes;\n4. Refusal to participate in this clinical study;\n5. Diagnosis of claustrophobia or other psychiatric disorders;\n6. Other conditions deemed by the investigator as inappropriate for participation in the trial.","ALL","18 Years","70 Years",{"count":65,"type":66},20,"ESTIMATED","INTERVENTIONAL",[69],"NA","This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors.\n\nThe 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread.\n\nIn this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using 68Ga-MY. The imaging results will be compared with 18F-FDG. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-MY PET\u002FCT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.",[72,73],"Lung Cancer","Breast Cancer","NOT_YET_RECRUITING","2026-05-08",{"date":77,"type":78},"2026-05-15","ACTUAL",{"date":80,"type":66},"2026-06-01",{"date":82,"type":66},"2027-12-30",{"name":5,"class":6},1]